Ocumetics Technology Corp
Recent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Ocumetics Technology Corp. (TSXV: OTC) is a Canada-based research and product development company specializing in adaptive lens designs for the ophthalmic industry. The company focuses on developing the Ocumetics Bionic Lens, an expandable accommodating intraocular lens that fits within the natural lens compartment of the eye, primarily targeting individuals over 45 years of age suffering from presbyopia, cataracts, or other age-related vision deterioration; it leverages the eye's natural ciliary muscle activity and zonules to enable seamless focus shifting from distance to near vision without the need for eyeglasses, contact lenses, or corrective surgery lag time. The proprietary lens design incorporates self-adapting suspension systems with cushions that conform to individual eye parameters, serving as a replaceable docking station for customized optics and future nanotechnologies. Founded in 2012 by Dr. Garth Webb, chief scientific officer, and headquartered at 1250, 639 - 5th Avenue S.W., Calgary, Alberta, Canada, Ocumetics operates in the preclinical and early clinical stages of its core technology, with ongoing research emphasizing safety, efficacy, and mass production feasibility for global patient care. The company conducts clinical studies, including surgical evaluations in Mexico City, reporting continued vision improvements in initial patient groups and surpassing early expectations in visual acuity outcomes. In the past two years, Ocumetics has advanced its first-in-human clinical trials, completing multiple surgical days and releasing positive interim data on patient vision recovery as part of its ongoing Mexico City study. The company announced a C$2.5 million brokered LIFE private placement in November 2025, led by Centurion One Capital Corp. as sole bookrunner, through the sale of up to 3.47 million units at C$0.72 each, with proceeds allocated to fund clinical trials, research and development, and general corporate purposes; an over-allotment option could raise an additional C$375,000. Previously known as Quantum Blockchain Technologies Ltd., Ocumetics rebranded in August 2021 to reflect its strategic shift to vision enhancement technologies.
Company News
Ocumetics Provides Summary of Group One Patient Clinical Progress
Ocumetics Announces Initiation of Patient Recruitment for Upcoming Group Two Human Clinical Surgeries
Ocumetics Completes Manufacturing of Next Generation Solid State Accommodating Intraocular Lenses for Upcoming Group Two First in Human Clinical Surgeries
Ocumetics Announces Completion of Third and Final Tranche of Unit Private Placement
Ocumetics Announces Completion of Second Tranche of Unit Private Placement
Ocumetics Announces Upsizing of Unit Private Placement
Ocumetics Announces Completion of First Tranche of Unit Private Placement
Ocumetics Announces Corporate and Operational Update as Positive Six-Month Clinical Results Advance Next Phase of First-in-Human Study
Ocumetics Announces Offering of Units
Ocumetics Announces Significant Debt Conversion Strengthening Balance Sheet Ahead of Patient Study Milestones
Ocumetics Accelerates Toward Group Two First-In-Human Study with Manufacturing Launch of Optimized Accommodating Lens
Ocumetics Announces Offering of Units
Ocumetics Reports Improvement in Six Month First-in-Human Results Meaningful Improvements in Patient Quality of Life
Ocumetics Technology Reports Attendance at ASCRS as Successful First-In-Human Trial Continues, No Material Change
Ocumetics to Showcase First-In-human Results with Industry Leaders & Potential Strategic Partners at ASCRS Annual Meeting
Ocumetics Technology Corp. Achieves Breakthrough in Next-Generation Accommodating Intraocular Lens Design
Ocumetics Announces Issuance of Stock Options
Ocumetics Announces Scientific Advisory Committee to Support Advancing Clinical and Regulatory Strategy
Ocumetics Announces Appointment of Raymond Marks to Board of Directors
Ocumetics Announces Forbearance Agreement for $4 Million Secured Convertible Debentures and Provides LIFE Offering Update